Investor Presentation: First Nine Months of 2020

45 Investor presentation First nine months of 2020 The global GLP-1 market penetration varies across regions with Novo Nordisk having a best-in-class portfolio GLP-1 market growth and Novo Nordisk market share GLP-1 value and patient share¹ of the total diabetes market 70% 60% 25% 24% 57.7% 20% 20% 47.6% 50% 40% 38.6% 15% 30% 10% 20% 5% 10% 0% 0% World 14% Thi 7% 5% 7% 2% Aug 2017 Aug 2020 NN market share Market growth NN share of growth NN growth America ■GLP-1 value share of total diabetes ■GLP-1 patient share of total diabetes North EMEA Region China ROW Source: 1Patient share based on data for the USA, the UK, Germany and France only. IQVIA MAT value, Aug 2020; EMEA: Europe, Middle East, Africa; RoW: Rest of World Novo NordiskⓇ

View entire presentation